institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published loading...Updated

Q&A Part 2: Reviewing the Significance of Lebrikizumab for Patients With Skin of Color, With Anabela Cardoso, MD

Summary by dermatologytimes.com
Anabela Cardoso, MD, reflects on specific data from the phase 3b ADmirable trial evaluating the safety and efficacy of lebrikizumab in patients with moderate to severe AD and pigmented skin.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

dermatologytimes.com broke the news in on Wednesday, July 2, 2025.
Sources are mostly out of (0)

You have read 1 out of your 5 free daily articles.